Infections in organ transplant recipients

Current Opinion in Infectious Diseases

Volumn 9, Issue 4, 1996, Pages 223-229

  Singh, Nina ^a   Yu, Victor L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIVIRUS AGENT; GANCICLOVIR;

CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HEPATITIS C; HEPATITIS VIRUS; HUMAN; HUMAN HERPESVIRUS 6; MYCOSIS; ORGAN TRANSPLANTATION; RECIPIENT; REVIEW; VIRUS INFECTION;

EID: 0029830153     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199608000-00003     Document Type: Review

References (52)

1. Reinke P, Fietze E, Odehakim S, Prosch S, Lippert J, Ewert R, Volk HD: Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994, 344:1737-1738.
2. Cakaloglu Y, Devlin J, Ogrady J, Sutherland S, Portmann BC, Heaton N, Tan KE, Williams R: Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995, 59:40-45.
3. Patel R, Smith TF, Espy M, Portela D, Wiesner RH, Krom RAF, Paya CV: • A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1995, 171:1010-1014. PCR of serum was proposed to be the best tool for initiating pre-emptive prophylaxis for CMV in liver transplant recipients.
4. Cunningham R, Harris A, Frankton A, Irving W: Detection of cytomegalovirus using PCR in serum from renal transplant recipients. J Clin Pathol 1995, 48:575-577.
5. Schmidt CA, Oettle H, Peng RQ, Neuhaus P, Blumhardt G, Lohmann R, Wilbom F, Osthoff K, Oertel J, Timm H et al.: Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995, 59:1133-1138.
6. Meyer-Konig U, Serr A, Vonlaer D, Kirste G, Wolff C, Haller O, Neumannhaefelin D, Hufert FT: Human cytomegalovirus immediate early and late transcripts in peripheral Wood leukocytes: diagnostic value in renal transplant recipients. J Infect Dis 1995, 171:705-709.
7. Bailey TC, Buller RS, Ettinger NA, Trulock EP, Gaudreaultkeener M, Langlois TM, Fornoff JER: Quantitative analysis of cytomegalovirus viremia in lung transplant recipients. J Infect Dis 1995, 171:1006-1010.
8. Grossi P, Minoli L, Percivalle E, Irish W, Vigano M, Gerna G: Clinical and virologlcal monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995, 59:847-851.
9. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC: Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995, 76:309-319.
10. Kuhn JE, Wendland T, Schafer P, Mohring K, Wieland U, Elgas M, Eggers KJ: Monitoring of renal allograft recipients by quantitation of human cytomegalovirus in peripheral blood leukocytes. J Med Virol 1994, 44:398-405.
11. Portela D, Patel R, Larsonkeller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RAF, Paya CV: OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995, 171:1014-1018.
12. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995, 123:18-26.
13. Aguado JM, Gomezsanchez MA, Lumbreras C, Delgado J, Lizasoaim M, Otero JR, Rufilanchas JJ, Nonega AR: Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995, 39:1643-1645.
14. Winston DJ, Wirin D, Snaked A, Busuttil RW: Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995, 346:69-74.
15. Kanj SS, Sharara AI, Clavien PA, Hamilton JA: Cytomegalovirus •• infection following liver transplantation: review of the literature. Clin Infect Dis 1996, 22:537-549. A state of the art review on CMV in liver transplant recipients.
16. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CGA, Paya CV: Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995, 20:1346-1353.
17. +) B lymphocytes. Transplantation 1995, 59:637-640.
18. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Cox K, Krams SM: Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995, 59:519-524.
19. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD: Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995, 59:135-138.
20. Singh N, Carrigan DR, Gayowski T, Singh J, Marino R: Variant B • human herpesvlrus associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient Trans-plantation 1995, 60:1355-1357. This report documents the pathogenicity of HHV-6 after liver transplantation.
21. Herbein G, Strasswimmer J, Altieri M, Woehl-Jaegle ML, Wolf P, Obert G: Longitudinal study of human herpesvirus-6 in organ transplant recipients. Clin Infect Dis 1996, 22:171-173.
22. Rady PL, Yen A, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tyring SK: Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 1995, 345:1339-1340.
23. Apalsch AM, Green M, Ledesmamedina J, Nour B, Wald ER: Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 1995, 20:394-399.
24. Sanchez-Tapias JM, Rodes J. Dilemmas of organ transplantation from anti-HCV-positive donors. Lancet 1995, 345:469-470.
25. Pereira BJG, Wright TL, Schmid CH, Levey AS: A controlled study of • hepatitis C transmission by organ transplantation. Lancet 1995, 345:484-487. Patient and graft survival were unaffected by donor anti-HCV status in this study.
26. Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, Ercilla G, Bruguera M, Andreu J, Carretero P et al.: Transplantation of kidneys from donors with hepatitis-C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995, 47:236-240.
27. Wang LF, Fung J, Rakela J, Demetris J, Mateo R, Pinna A, Tsamandas A, Germer J, Vargas H, Laskus T: HCV genotypes and outcome in HCV infected cirrhotic patients receiving liver transplant from HCV positive donors [Abstract]. Hepatology 1995, 22:151.
28. Goetz AM, Ndimbie OK, Wagener MM, Muder RR: Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center. Transplantation 1995, 59:990-994.
29. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J: De-novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995, 59:1676-1682.
30. Singh N, Gayowski T, Wagener MM, Marino IR: Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996, 61:402-406.
31. Singh N, Gayowski T, Wannstedt CF, Marino IR: Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long term response with maintenance therapy. Clin Transplant (in press).
32. Ghalib R, Orian P, Ritter J, White H, Lowell J, Howard T, Peters M: Treatment of HCV after solid organ transplant with alpha 2B-interferon [Abstract]. Hepatology 1995, 22:132.
33. Ruder H, Kerling F, Daniel V, Korn K, Wassmuth R: Decreased • alloreactivity after vaccination against hepatitis B. Transplantation 1995, 59:1339-1342. The authors propose a novel explanation for the disappearance of the transfusion effect in renal transplant recipients, i.e. decreased alloreactivity after HBV vaccination mimicking the transfusion effect.
34. Michaels MG, Lanford R, Demetris AJ, Chavez D, Brasky K, Fung J, • Starzl TE: Lack of susceptibility of baboons to infection with hepatitis B virus. Transplantation 1996, 61:350-351. This study corroborates the historical belief that baboons are resistant to HBV.
35. +), HBIgM( ) organ donors. Transplantation 1995, 59:230-234.
36. Berenguer M, Terrault WA, Piatak M, Yun A, Kim JP, Lake JR, Roberts JP, Ascher NL, Wright TL: Hepatitis G virus (HGV) in hepatitis C virus (HCV) infection following liver transplantation [Abstract], Hepatology 1995, 22:151.
37. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R: Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995, 21:1328-1336.
38. Briegel J, Forst H, Spill B, Haas A, Grabein B, Hadler M, Kilger E, Jauch KW, Maag K, Ruckdeschel G et al.: Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995, 14:375-382.
39. Singh N, Gayowski T, Singh J, Yu VL: Invasive gastrointestinal zygomycosis in liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 1995, 20:617-620.
40. Fakih MG, Barden GE, Oakes CV, Berenson CS: First reported case of Aspergillus granulosus Infection in a cardiac transplant patient. J Clin Microbiol 1995, 33:471-473.
41. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O: • Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients - a randomized, placebo-controlled study. Transplantation 1995, 59:45-50. In this study liposomal amphotericin B was effective as prophylaxis against invasive candidiasis although the number of infections caused by Aspergillus spp. was insufficient for assessment of the efficacy against aspergillosis.
42. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia, consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis 1993, 17:906-908.
43. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of • amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995, 21:1145-1153. This study showed that the newer amphotericin B preparations may be preferable drugs for the treatment of invasive fungal infections requiring amphotericin B in transplant recipients. The remarkably safe nephrotoxicity profile of these preparations is a highly desirable feature because renal failure has been shown to be an independent marker for increased mortality in liver transplant recipients.
44. Linden PK, Pasculle AW, Marnez R, Kramer DJ, Fung JJ, Pinner AD, Kusne S: Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin susceptible E. faecium. Clin Infect Dis 1996, 22:663-670.
45. Everett JE, Wahoff DC, Statz C, Gillingham KJ, Gruessner A, Gruessner RWG, Gores PF, Sutherland DER, Dunn DL: Characterization and impact of wound infection after pancreas transplantation. Arch Surg 1994, 129:1310-1317.
46. Marrie TJ, Johnson WM, Tyler SD, Bezanson GS, Burbridge S: Genomic stability of Legionella pneumophila isolates recovered from two cardiac transplant patients with nosocomial legionnaires' disease. J Clin Microbiol 1994, 32:3085-3087.
47. Bangsborg JM, Uldum S, Jensen JS, Bruun BG: Nosocomial • legionellosis in three heart-lung transplant patients: case reports and environmental observations. Eur J Clin Microbiol Infect Dis 1995. 14:99-104. This study reports on two heart transplant patients and one double-lung transplant patient who contracted L. pneumophila postoperatively. The source of the organism may have been the ice machine. Oral roxithromycin proved effective.
48. Levin, AS, Gobara S, Scarpitta CM, Warschauer CL, Sinto SI, Rodrigues E, Mendes CMF, Sabbaga E, Boulos M, and the Legionellosis study team: Electric showers as a control measure for Legionella spp. in a renal transplant unit in Sao Paulo, Brazil. J Hosp Infect 1995, 30:133-137.
49. Singh N, Gayowski T, Wagener MM, Marino IR, Yu VL: Pulmonary infections in liver transplant recipients receiving tacrolimus as primary immunosuppression: changing pattern of microbial etiologies. Transplantation 1996, 61:396-401.
50. Marrie TJ, Johnson W, Tyler S, Bezanson G, Haldane D, Burbndge S, Joly J: Potable water and nosocomial Legionnaires' disease - check water from all rooms in which patient has stayed. Epidemiol Infect 1995, 114:267-276.
51. Orr KE, Gould FK, Shoret G, Dark JH, Hilton CJ, Corris PA, Freeman R: Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect Dis 1994, 29:249-253.
52. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM: Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995, 59:851-859.